Enabling reliable skin drug delivery and patient comfort

Our skin – an overlooked optimal site for skin drug delivery and vaccination

Skin drug delivery or intradermal injection (i.e. injection in the dermal layer of the skin) offers great benefits for both prophylactic and therapeutic vaccines.  Why? The skin is our first line of defense offering a dense network of immune cells. Indeed, for prophylactic vaccines there is a clear dose-sparing potential as only 1/10th of the dose is needed compared to intramuscular and subcutaneous administration. Also, the rich immune network offers beneficial benefits for therapeutic drug delivery, including cell therapy and cancer immunotherapy.

Our solution – VAX-ID

VAX-ID® is the heart of Idevax, an ISO13485:2016 certified company. It is an award-winning patented drug delivery device suited for reliable intradermal injection with high ease of use. Devices are currently available for investigational use only (IUO) and research use only (RUO). CE marking and FDA approval are expected in the upcoming months.

Benefits VAX-ID

Latest news:

Welcoming a new intern to our Scientific and Clinical Affairs team, Amélie Donck

This summer we welcome, Malé Geerts, as a new intern at IDEVAX

Highlights of the first 6 months of 2024

Upcoming events:

Flanders Vaccine Symposium 2024

Elsevier Vaccine Conference 2024